Biogen Celebrates 40 Years as a Pioneer in Neuroscience

Members of the Media are Invited to Join Us for Our 40th Anniversary Event

“Biogen in Neuroscience: Past, Present & Future”

Biogen (Nasdaq: BIIB):

Who/What:On Monday, May 14, 2018, Biogen (Nasdaq: BIIB), one of the world’s first global biotechnology companies, will commemorate its 40th anniversary with a special event to celebrate its pursuit of innovation and commitment to making a difference in the lives of patients with serious diseases.

In honor of the occasion, Michel Vounatsos, Chief Executive Officer and Chairman of the Board Stelios Papadopoulos, Ph.D., will be joined by Biogen Founders, employees, patient advocates and other members of the community to celebrate Biogen’s legacy and growth to a company with $12 billion in annual revenue and more than 7,000 employees, and to showcase its plans to advance the future of neuroscience.

When/Where:Monday, May 14, 2018Massachusetts Institute of Technology, Kresge Auditorium, Cambridge, MA1:00 PM – 3:00 PM

Program:

• 1:00 PM — Remarks from Michel Vounatsos, Chief Executive Officer; Stelios Papadopoulos, Chairman of the Board; and founders Walter Gilbert, Phillip Sharp and Charles Weissmann
• 1:45 PM – Pioneering Neuroscience with Al Sandrock, Chief Medical Officer, and Michael Ehlers, EVP, Research & Development
• 2:15 PM – The Future of Neuroscience Panel, programmed by The Economist Events

3:00 PM: Celebratory Reception

RSVP:Media interested in attending the event may contact David Caouette, Leader, Global Media Relations, at [email protected] or 617.679.4945 (ext 84945).

ABOUT BIOGENAt Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, MS and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180507005171/en/

Biogen
David Caouette, 617-679-4945 (ext 84945)
Leader, Global Media Relations
[email protected]

Source: Biogen

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Biogen (BIIB) call put ratio 3.7 calls to 1 put with a focus on September calls
• Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
• Man Group PLC : Form 8.3 - Rotork plc